Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes
Open accessThe DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index.
Abstract
Purpose of review: The antiobesity effects of activation of hypothalamic neuropeptide Y2 receptors (NPYR2) by the gut-derived hormone, peptide YY (PYY), are established. However, more recent insight into the biology of PYY has demonstrated remarkable benefits of sustained activation of pancreatic beta-cell NPYR1, that promises to open a new therapeutic avenue in diabetes. Recent findings: The therapeutic applicability of NPYR2 agonists for obesity has been considered for many years. An alternative pathway for the clinical realisation of PYY-based drugs could be related to the development of NPYR1 agonists for treatment of diabetes. Thus, although stimulation of NPYR1 on pancreatic beta-cells has immediate insulinostatic effects, prolonged activation of these receptors leads to well defined beta-cell protective effects, with obvious positive implications for the treatment of diabetes. In this regard, NPYR1-specific, long-acting enzyme resistant PYY analogues, have been recently developed with encouraging preclinical effects observed on pancreatic islet architecture in diabetes. In agreement, the benefits of certain types of bariatric surgeries on beta-cell function and responsiveness have also been linked to elevated PYY secretion and NPY1 receptor activation. Summary: Enzymatically stable forms of PYY, that selectively activate NPYR1, may have significant potential for preservation of beta-cell mass and the treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Peptide tyrosine tyrosine (PYY) is known to exert a strong anorectic effect and initial clinical studies are in progress with long-acting PYY analogues alone and in combination with a GLP-1RA for the treatment of obesity [39].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 2×
“Much of the initial therapeutic focus on PYY revolved around PYY (3–36) peptides, and related NPYR2 activation, for the potential management of obesity [17,19,22].”
BackgroundRoux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
Beta Cell Dysfunction and Insulin Resistance
Cerf, M. E. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00037 · Cited by 964
Tatemoto, K. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.8.2514 · Cited by 612
Effect of Peptide YY3–36 on Food Intake in Humans
Degen, L., Oesch, S., Casanova, M., Graf, S., Ketterer, S., Drewe, J., & Beglinger, C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.001 · Cited by 366
De Silva, A., Salem, V., Long, C. J., Makwana, A., Newbould, R. D., Rabiner, E. A., Ghatei, M. A., Bloom, S. R., Matthews, P. M., Beaver, J. D., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.09.010 · Cited by 353
The L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198 · cited 1×
“with proglucagon-derived hormones, namely glucagon-like peptide-1 (GLP-1), GLP-2, glicentin and oxyntomodulin [2].”
BackgroundNeuropeptide Y feeding receptors: are multiple subtypes involved?
Inui, A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01303-6 · Cited by 198
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents
Ye, J., Hao, Z., Mumphrey, M. B., Townsend, R. L., Patterson, L. M., Stylopoulos, N., Münzberg, H., Morrison, C. D., Drucker, D. J., & Berthoud, H.-R. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00491.2013 · Cited by 174
Cited by
A gut-derived hormone suppresses sugar appetite and regulates food choice in Drosophila
Malita, A., Kubrak, O. I., Koyama, T., Ahrentløv, N., Texada, M. J., Nagy, S., Halberg, K. A., & Rewitz, K. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00672-z · Cited by 127
Wang, Y., Zhao, J., Qin, Y., Yu, Z., Zhang, Y., Ning, X., & Sun, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908219 · Cited by 110
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Self-citationPancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes
Zhu, W., Tanday, N., Flatt, P. R., & Irwin, N. (2022) · Peptides · doi:10.1016/j.peptides.2022.170923 · Cited by 58
Self-citationNeuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies
Sánchez, M. L., Rodriguez, F. D., & Coveñas, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129962 · Cited by 56
Metadata
- Authors
- Lafferty, R. A., Flatt, P. R., & Irwin, N.
- Affiliations
- University of Ulster (GB)
- Corresponding author
- Irwin, Nigel
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2020-12-30
- Volume
- 28
- Issue
- 2
- Pages
- 253-261
- ISSN
- 1752-296X (ISSN-L)
- 1752-2978
- OpenAlex
- W3120340222
- Cited by
- 42
- References
- 69
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 14 · 2021: 5
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- green
- pure.ulster.ac.uk
- Licence
- other-oa
- Locations
- Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion)
- PubMed (publishedVersion)
- Ulster University Research Portal (Ulster University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- peptide YY, pancreatic beta cells, obesity, diabetes mellitus, insulin secretion, beta-cell protection, bariatric surgery
- MeSH terms
- Diabetes Mellitus, Humans, Islets of Langerhans, Obesity, Peptide YY, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes. https://app.cochat.ai/papers/10.1097/med.0000000000000612
- The paper
- Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021). Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/med.0000000000000612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.